Martee L. Hensley, J. Kyle Wathen, Robert G. Maki, Dejka M. Araujo, Gregory Sutton, Dennis A. Priebat, Suzanne George, Robert A. Soslow and Laurence H. Baker Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma Cancer 119
Version of Record online: 18 JAN 2013 | DOI: 10.1002/cncr.27942
Among women with high-grade, uterus-limited leiomyosarcoma who receive treatment with adjuvant gemcitabine plus docetaxel followed by doxorubicin, 78% remain progression-free at 2 years, and 57% remain progression-free at 3 years.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field